
    
      Patients receive carfilzomib, pomalidomide, and dexamethasone in 28 days treatment cycles.
      Study treatment continues for as long a their myeloma does not worsen and they do not have
      unacceptable side effects. After completion of study treatment, patients are followed for up
      to 2 years.
    
  